TY - JOUR AU - Hodi, F. S. AU - O'Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. AU - Haanen, J. B. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Schadendorf, D. AU - Hodi, F. S. AU - Robert, C. AU - Weber, J. S. AU - Margolin, K. AU - Hamid, O. PY - 2015 DA - 2015// TI - Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.56.2736 DO - 10.1200/JCO.2014.56.2736 ID - Schadendorf2015 ER - TY - JOUR AU - Chen, L. T. AU - Satoh, T. AU - Ryu, M. H. AU - Chao, Y. AU - Kato, K. AU - Chung, H. C. PY - 2020 DA - 2020// TI - A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data JO - Gastric Cancer VL - 23 UR - https://doi.org/10.1007/s10120-019-01034-7 DO - 10.1007/s10120-019-01034-7 ID - Chen2020 ER - TY - JOUR AU - Kato, K. AU - Cho, B. C. AU - Takahashi, M. AU - Okada, M. AU - Lin, C. Y. AU - Chin, K. PY - 2019 DA - 2019// TI - Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial JO - Lancet Oncol VL - 20 UR - https://doi.org/10.1016/S1470-2045(19)30626-6 DO - 10.1016/S1470-2045(19)30626-6 ID - Kato2019 ER - TY - JOUR AU - Brahmer, J. R. AU - Tykodi, S. S. AU - Chow, L. Q. AU - Hwu, W. J. AU - Topalian, S. L. AU - Hwu, P. PY - 2012 DA - 2012// TI - Safety and activity of anti-PD-L1 antibody in patients with advanced cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200694 DO - 10.1056/NEJMoa1200694 ID - Brahmer2012 ER - TY - JOUR AU - Herbst, R. S. AU - Baas, P. AU - Kim, D. W. AU - Felip, E. AU - Perez-Gracia, J. L. AU - Han, J. Y. PY - 2016 DA - 2016// TI - Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial JO - Lancet. VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)01281-7 DO - 10.1016/S0140-6736(15)01281-7 ID - Herbst2016 ER - TY - JOUR AU - Rosenberg, J. E. AU - Hoffman-Censits, J. AU - Powles, T. AU - Heijden, M. S. AU - Balar, A. V. AU - Necchi, A. PY - 2016 DA - 2016// TI - Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial JO - Lancet. VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00561-4 DO - 10.1016/S0140-6736(16)00561-4 ID - Rosenberg2016 ER - TY - JOUR AU - Topalian, S. L. AU - Hodi, F. S. AU - Brahmer, J. R. AU - Gettinger, S. N. AU - Smith, D. C. AU - McDermott, D. F. PY - 2012 DA - 2012// TI - Safety, activity, and immune correlates of anti-PD-1 antibody in cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200690 DO - 10.1056/NEJMoa1200690 ID - Topalian2012 ER - TY - JOUR AU - Wolchok, J. D. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Rutkowski, P. AU - Grob, J. J. AU - Cowey, C. L. PY - 2017 DA - 2017// TI - Overall survival with combined nivolumab and ipilimumab in advanced melanoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1709684 DO - 10.1056/NEJMoa1709684 ID - Wolchok2017 ER - TY - JOUR AU - Wei, S. C. AU - Duffy, C. R. AU - Allison, J. P. PY - 2018 DA - 2018// TI - Fundamental mechanisms of immune checkpoint blockade therapy JO - Cancer Discov. VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0367 DO - 10.1158/2159-8290.CD-18-0367 ID - Wei2018 ER - TY - JOUR AU - Sosa, A. AU - Lopez Cadena, E. AU - Simon Olive, C. AU - Karachaliou, N. AU - Rosell, R. PY - 2018 DA - 2018// TI - Clinical assessment of immune-related adverse events JO - Ther Adv Med Oncol VL - 10 UR - https://doi.org/10.1177/1758835918764628 DO - 10.1177/1758835918764628 ID - Sosa2018 ER - TY - JOUR AU - Brunner, M. C. AU - Chambers, C. A. AU - Chan, F. K. AU - Hanke, J. AU - Winoto, A. AU - Allison, J. P. PY - 1999 DA - 1999// TI - CTLA-4-mediated inhibition of early events of T cell proliferation JO - J Immunol VL - 162 ID - Brunner1999 ER - TY - JOUR AU - Egen, J. G. AU - Allison, J. P. PY - 2002 DA - 2002// TI - Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength JO - Immunity. VL - 16 UR - https://doi.org/10.1016/S1074-7613(01)00259-X DO - 10.1016/S1074-7613(01)00259-X ID - Egen2002 ER - TY - JOUR AU - Pentcheva-Hoang, T. AU - Egen, J. G. AU - Wojnoonski, K. AU - Allison, J. P. PY - 2004 DA - 2004// TI - B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse JO - Immunity. VL - 21 UR - https://doi.org/10.1016/j.immuni.2004.06.017 DO - 10.1016/j.immuni.2004.06.017 ID - Pentcheva-Hoang2004 ER - TY - JOUR AU - Linsley, P. S. AU - Brady, W. AU - Urnes, M. AU - Grosmaire, L. S. AU - Damle, N. K. AU - Ledbetter, J. A. PY - 1991 DA - 1991// TI - CTLA-4 is a second receptor for the B cell activation antigen B7 JO - J Exp Med VL - 174 UR - https://doi.org/10.1084/jem.174.3.561 DO - 10.1084/jem.174.3.561 ID - Linsley1991 ER - TY - JOUR AU - Linsley, P. S. AU - Greene, J. L. AU - Brady, W. AU - Bajorath, J. AU - Ledbetter, J. A. AU - Peach, R. PY - 1994 DA - 1994// TI - Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors JO - Immunity. VL - 1 UR - https://doi.org/10.1016/S1074-7613(94)80021-9 DO - 10.1016/S1074-7613(94)80021-9 ID - Linsley1994 ER - TY - JOUR AU - Merwe, P. A. AU - Bodian, D. L. AU - Daenke, S. AU - Linsley, P. AU - Davis, S. J. PY - 1997 DA - 1997// TI - CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics JO - J Exp Med VL - 185 UR - https://doi.org/10.1084/jem.185.3.393 DO - 10.1084/jem.185.3.393 ID - Merwe1997 ER - TY - JOUR AU - Friedline, R. H. AU - Brown, D. S. AU - Nguyen, H. AU - Kornfeld, H. AU - Lee, J. AU - Zhang, Y. PY - 2009 DA - 2009// TI - CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance JO - J Exp Med VL - 206 UR - https://doi.org/10.1084/jem.20081811 DO - 10.1084/jem.20081811 ID - Friedline2009 ER - TY - JOUR AU - Read, S. AU - Greenwald, R. AU - Izcue, A. AU - Robinson, N. AU - Mandelbrot, D. AU - Francisco, L. PY - 2006 DA - 2006// TI - Blockade of CTLA-4 on CD4 + CD25+ regulatory T cells abrogates their function in vivo JO - J Immunol VL - 177 UR - https://doi.org/10.4049/jimmunol.177.7.4376 DO - 10.4049/jimmunol.177.7.4376 ID - Read2006 ER - TY - JOUR AU - Jain, N. AU - Nguyen, H. AU - Chambers, C. AU - Kang, J. PY - 2010 DA - 2010// TI - Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.0910341107 DO - 10.1073/pnas.0910341107 ID - Jain2010 ER - TY - JOUR AU - Wing, K. AU - Onishi, Y. AU - Prieto-Martin, P. AU - Yamaguchi, T. AU - Miyara, M. AU - Fehervari, Z. PY - 2008 DA - 2008// TI - CTLA-4 control over Foxp3+ regulatory T cell function JO - Science. VL - 322 UR - https://doi.org/10.1126/science.1160062 DO - 10.1126/science.1160062 ID - Wing2008 ER - TY - JOUR AU - Boasso, A. AU - Herbeuval, J. P. AU - Hardy, A. W. AU - Winkler, C. AU - Shearer, G. M. PY - 2005 DA - 2005// TI - Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-fc in human CD4+ T cells JO - Blood. VL - 105 UR - https://doi.org/10.1182/blood-2004-06-2089 DO - 10.1182/blood-2004-06-2089 ID - Boasso2005 ER - TY - JOUR AU - Qureshi, O. S. AU - Zheng, Y. AU - Nakamura, K. AU - Attridge, K. AU - Manzotti, C. AU - Schmidt, E. M. PY - 2011 DA - 2011// TI - Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 JO - Science. VL - 332 UR - https://doi.org/10.1126/science.1202947 DO - 10.1126/science.1202947 ID - Qureshi2011 ER - TY - JOUR AU - Corse, E. AU - Allison, J. P. PY - 2012 DA - 2012// TI - Cutting edge: CTLA-4 on effector T cells inhibits in trans JO - J Immunol VL - 189 UR - https://doi.org/10.4049/jimmunol.1200695 DO - 10.4049/jimmunol.1200695 ID - Corse2012 ER - TY - JOUR AU - Ovcinnikovs, V. AU - Ross, E. M. AU - Petersone, L. AU - Edner, N. M. AU - Heuts, F. AU - Ntavli, E. PY - 2019 DA - 2019// TI - CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells JO - Sci Immunol VL - 4 UR - https://doi.org/10.1126/sciimmunol.aaw0902 DO - 10.1126/sciimmunol.aaw0902 ID - Ovcinnikovs2019 ER - TY - JOUR AU - Qureshi, O. S. AU - Kaur, S. AU - Hou, T. Z. AU - Jeffery, L. E. AU - Poulter, N. S. AU - Briggs, Z. PY - 2012 DA - 2012// TI - Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation JO - J Biol Chem VL - 287 UR - https://doi.org/10.1074/jbc.M111.304329 DO - 10.1074/jbc.M111.304329 ID - Qureshi2012 ER - TY - JOUR AU - Lo, B. AU - Zhang, K. AU - Lu, W. AU - Zheng, L. AU - Zhang, Q. AU - Kanellopoulou, C. PY - 2015 DA - 2015// TI - AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy JO - Science. VL - 349 UR - https://doi.org/10.1126/science.aaa1663 DO - 10.1126/science.aaa1663 ID - Lo2015 ER - TY - JOUR AU - Charbonnier, L. M. AU - Janssen, E. AU - Chou, J. AU - Ohsumi, T. K. AU - Keles, S. AU - Hsu, J. T. PY - 2015 DA - 2015// TI - Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA JO - J Allergy Clin Immunol VL - 135 UR - https://doi.org/10.1016/j.jaci.2014.10.019 DO - 10.1016/j.jaci.2014.10.019 ID - Charbonnier2015 ER - TY - JOUR AU - Boutros, C. AU - Tarhini, A. AU - Routier, E. AU - Lambotte, O. AU - Ladurie, F. L. AU - Carbonnel, F. PY - 2016 DA - 2016// TI - Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination JO - Nat Rev Clin Oncol VL - 13 UR - https://doi.org/10.1038/nrclinonc.2016.58 DO - 10.1038/nrclinonc.2016.58 ID - Boutros2016 ER - TY - JOUR AU - Zhang, Y. AU - Du, X. AU - Liu, M. AU - Tang, F. AU - Zhang, P. AU - Ai, C. PY - 2019 DA - 2019// TI - Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy JO - Cell Res VL - 29 UR - https://doi.org/10.1038/s41422-019-0184-1 DO - 10.1038/s41422-019-0184-1 ID - Zhang2019 ER - TY - JOUR AU - Dong, H. AU - Zhu, G. AU - Tamada, K. AU - Chen, L. PY - 1999 DA - 1999// TI - B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion JO - Nat Med VL - 5 UR - https://doi.org/10.1038/70932 DO - 10.1038/70932 ID - Dong1999 ER - TY - JOUR AU - Freeman, G. J. AU - Long, A. J. AU - Iwai, Y. AU - Bourque, K. AU - Chernova, T. AU - Nishimura, H. PY - 2000 DA - 2000// TI - Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation JO - J Exp Med VL - 192 UR - https://doi.org/10.1084/jem.192.7.1027 DO - 10.1084/jem.192.7.1027 ID - Freeman2000 ER - TY - JOUR AU - Latchman, Y. AU - Wood, C. R. AU - Chernova, T. AU - Chaudhary, D. AU - Borde, M. AU - Chernova, I. PY - 2001 DA - 2001// TI - PD-L2 is a second ligand for PD-1 and inhibits T cell activation JO - Nat Immunol VL - 2 UR - https://doi.org/10.1038/85330 DO - 10.1038/85330 ID - Latchman2001 ER - TY - JOUR AU - Yokosuka, T. AU - Takamatsu, M. AU - Kobayashi-Imanishi, W. AU - Hashimoto-Tane, A. AU - Azuma, M. AU - Saito, T. PY - 2012 DA - 2012// TI - Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 JO - J Exp Med VL - 209 UR - https://doi.org/10.1084/jem.20112741 DO - 10.1084/jem.20112741 ID - Yokosuka2012 ER - TY - JOUR AU - Hui, E. AU - Cheung, J. AU - Zhu, J. AU - Su, X. AU - Taylor, M. J. AU - Wallweber, H. A. PY - 2017 DA - 2017// TI - T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition JO - Science. VL - 355 UR - https://doi.org/10.1126/science.aaf1292 DO - 10.1126/science.aaf1292 ID - Hui2017 ER - TY - JOUR AU - Kamphorst, A. O. AU - Wieland, A. AU - Nasti, T. AU - Yang, S. AU - Zhang, R. AU - Barber, D. L. PY - 2017 DA - 2017// TI - Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent JO - Science. VL - 355 UR - https://doi.org/10.1126/science.aaf0683 DO - 10.1126/science.aaf0683 ID - Kamphorst2017 ER - TY - JOUR AU - Shimizu, K. AU - Sugiura, D. AU - Okazaki, I. M. AU - Maruhashi, T. AU - Takegami, Y. AU - Cheng, C. PY - 2020 DA - 2020// TI - PD-1 imposes qualitative control of cellular transcriptomes in response to T cell activation JO - Mol Cell VL - 77 UR - https://doi.org/10.1016/j.molcel.2019.12.012 DO - 10.1016/j.molcel.2019.12.012 ID - Shimizu2020 ER - TY - JOUR AU - Zhao, Y. AU - Harrison, D. L. AU - Song, Y. AU - Ji, J. AU - Huang, J. AU - Hui, E. PY - 2018 DA - 2018// TI - Antigen-presenting cell-intrinsic PD-1 neutralizes PD-L1 in cis to attenuate PD-1 signaling in T cells JO - Cell Rep VL - 24 UR - https://doi.org/10.1016/j.celrep.2018.06.054 DO - 10.1016/j.celrep.2018.06.054 ID - Zhao2018 ER - TY - JOUR AU - Chaudhri, A. AU - Xiao, Y. AU - Klee, A. N. AU - Wang, X. AU - Zhu, B. AU - Freeman, G. J. PY - 2018 DA - 2018// TI - PD-L1 binds to B7-1 only in cis on the same cell surface JO - Cancer Immunol Res. VL - 6 UR - https://doi.org/10.1158/2326-6066.CIR-17-0316 DO - 10.1158/2326-6066.CIR-17-0316 ID - Chaudhri2018 ER - TY - JOUR AU - Sugiura, D. AU - Maruhashi, T. AU - Okazaki, I. M. AU - Shimizu, K. AU - Maeda, T. K. AU - Takemoto, T. PY - 2019 DA - 2019// TI - Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses JO - Science. VL - 364 UR - https://doi.org/10.1126/science.aav7062 DO - 10.1126/science.aav7062 ID - Sugiura2019 ER - TY - JOUR AU - Zhao, Y. AU - Lee, C. K. AU - Lin, C. H. AU - Gassen, R. B. AU - Xu, X. AU - Huang, Z. PY - 2019 DA - 2019// TI - PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways JO - Immunity VL - 51 UR - https://doi.org/10.1016/j.immuni.2019.11.003 DO - 10.1016/j.immuni.2019.11.003 ID - Zhao2019 ER - TY - JOUR AU - Chen, G. AU - Huang, A. C. AU - Zhang, W. AU - Zhang, G. AU - Wu, M. AU - Xu, W. PY - 2018 DA - 2018// TI - Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response JO - Nature. VL - 560 UR - https://doi.org/10.1038/s41586-018-0392-8 DO - 10.1038/s41586-018-0392-8 ID - Chen2018 ER - TY - JOUR AU - Rossille, D. AU - Gressier, M. AU - Damotte, D. AU - Maucort-Boulch, D. AU - Pangault, C. AU - Semana, G. PY - 2014 DA - 2014// TI - High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial JO - Leukemia. VL - 28 UR - https://doi.org/10.1038/leu.2014.137 DO - 10.1038/leu.2014.137 ID - Rossille2014 ER - TY - JOUR AU - Lin, H. AU - Wei, S. AU - Hurt, E. M. AU - Green, M. D. AU - Zhao, L. AU - Vatan, L. PY - 2018 DA - 2018// TI - Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression JO - J Clin Invest VL - 128 UR - https://doi.org/10.1172/JCI96113 DO - 10.1172/JCI96113 ID - Lin2018 ER - TY - JOUR AU - Dakappagari, N. AU - Ho, S. N. AU - Gascoyne, R. D. AU - Ranuio, J. AU - Weng, A. P. AU - Tangri, S. PY - 2012 DA - 2012// TI - CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma JO - Cytometry B Clin Cytom VL - 82 UR - https://doi.org/10.1002/cyto.b.20631 DO - 10.1002/cyto.b.20631 ID - Dakappagari2012 ER - TY - JOUR AU - Ansell, S. M. AU - Lesokhin, A. M. AU - Borrello, I. AU - Halwani, A. AU - Scott, E. C. AU - Gutierrez, M. PY - 2015 DA - 2015// TI - PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411087 DO - 10.1056/NEJMoa1411087 ID - Ansell2015 ER - TY - JOUR AU - Armand, P. AU - Engert, A. AU - Younes, A. AU - Fanale, M. AU - Santoro, A. AU - Zinzani, P. L. PY - 2018 DA - 2018// TI - Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.76.0793 DO - 10.1200/JCO.2017.76.0793 ID - Armand2018 ER - TY - JOUR AU - Ramchandren, R. AU - Domingo-Domènech, E. AU - Rueda, A. AU - Trněný, M. AU - Feldman, T. A. AU - Lee, H. J. PY - 2019 DA - 2019// TI - Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.19.00315 DO - 10.1200/JCO.19.00315 ID - Ramchandren2019 ER - TY - JOUR AU - Armand, P. AU - Shipp, M. A. AU - Ribrag, V. AU - Michot, J. M. AU - Zinzani, P. L. AU - Kuruvilla, J. PY - 2016 DA - 2016// TI - Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.67.3467 DO - 10.1200/JCO.2016.67.3467 ID - Armand2016 ER - TY - JOUR AU - Chen, R. AU - Zinzani, P. L. AU - Fanale, M. A. AU - Armand, P. AU - Johnson, N. A. AU - Brice, P. PY - 2017 DA - 2017// TI - Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.72.1316 DO - 10.1200/JCO.2016.72.1316 ID - Chen2017 ER - TY - JOUR AU - Ansell, S. M. AU - Minnema, M. C. AU - Johnson, P. AU - Timmerman, J. M. AU - Armand, P. AU - Shipp, M. A. PY - 2019 DA - 2019// TI - Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.18.00766 DO - 10.1200/JCO.18.00766 ID - Ansell2019 ER - TY - JOUR AU - Nastoupil, L. J. AU - Westin, J. R. AU - Fowler, N. H. AU - Fanale, M. A. AU - Samaniego, F. AU - Oki, Y. PY - 2017 DA - 2017// TI - Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.7519 DO - 10.1200/JCO.2017.35.15_suppl.7519 ID - Nastoupil2017 ER - TY - JOUR AU - Barraclough, A. AU - Chong, G. AU - Gilbertson, M. AU - Grigg, A. AU - Churilov, L. AU - Fancourt, T. PY - 2019 DA - 2019// TI - Immune priming with single-agent nivolumab followed by combined nivolumab & rituximab is safe and efficacious for first-line treatment of follicular lymphoma; interim snalysis of the ‘1st FLOR’ study JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-123908 DO - 10.1182/blood-2019-123908 ID - Barraclough2019 ER - TY - JOUR AU - Iyer, S. P. AU - Neelapu, S. S. AU - Burns, E. AU - Nair, R. AU - Hosing, C. AU - Nieto, Y. PY - 2019 DA - 2019// TI - A phase I/II study to examine the safety and efficacy of pembrolizumab 200 mg fixed dose administered every 3 weeks (Q3W) in combination with romidepsin in relapsed or refractory peripheral T-cell lymphoma (PTCL) JO - Blood VL - 134 UR - https://doi.org/10.1182/blood-2019-132278 DO - 10.1182/blood-2019-132278 ID - Iyer2019 ER - TY - JOUR AU - Khodadoust, M. S. AU - Rook, A. H. AU - Porcu, P. AU - Foss, F. AU - Moskowitz, A. J. AU - Shustov, A. PY - 2020 DA - 2020// TI - Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.19.01056 DO - 10.1200/JCO.19.01056 ID - Khodadoust2020 ER - TY - JOUR AU - Mateos, M. V. AU - Orlowski, R. Z. AU - Ocio, E. M. AU - Rodriguez-Otero, P. AU - Reece, D. AU - Moreau, P. PY - 2019 DA - 2019// TI - Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study JO - Br J Haematol VL - 186 UR - https://doi.org/10.1111/bjh.15946 DO - 10.1111/bjh.15946 ID - Mateos2019 ER - TY - JOUR AU - Mateos, M. V. AU - Blacklock, H. AU - Schjesvold, F. AU - Oriol, A. AU - Simpson, D. AU - George, A. PY - 2019 DA - 2019// TI - Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial JO - Lancet Haematol. VL - 6 UR - https://doi.org/10.1016/S2352-3026(19)30110-3 DO - 10.1016/S2352-3026(19)30110-3 ID - Mateos2019 ER - TY - JOUR AU - Usmani, S. Z. AU - Schjesvold, F. AU - Oriol, A. AU - Karlin, L. AU - Cavo, M. AU - Rifkin, R. M. PY - 2019 DA - 2019// TI - Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial JO - Lancet Haematol. VL - 6 UR - https://doi.org/10.1016/S2352-3026(19)30109-7 DO - 10.1016/S2352-3026(19)30109-7 ID - Usmani2019 ER - TY - JOUR AU - Davids, M. S. AU - Kim, H. T. AU - Bachireddy, P. AU - Costello, C. AU - Liguori, R. AU - Savell, A. PY - 2016 DA - 2016// TI - Ipilimumab for patients with relapse after allogeneic transplantation JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1601202 DO - 10.1056/NEJMoa1601202 ID - Davids2016 ER - TY - JOUR AU - Daver, N. AU - Garcia-Manero, G. AU - Basu, S. AU - Boddu, P. C. AU - Alfayez, M. AU - Cortes, J. E. PY - 2019 DA - 2019// TI - Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study JO - Cancer Discov. VL - 9 UR - https://doi.org/10.1158/2159-8290.CD-18-0774 DO - 10.1158/2159-8290.CD-18-0774 ID - Daver2019 ER - TY - JOUR AU - Younes, A. AU - Santoro, A. AU - Shipp, M. AU - Zinzani, P. L. AU - Timmerman, J. M. AU - Ansell, S. PY - 2016 DA - 2016// TI - Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial JO - Lancet Oncol. VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30167-X DO - 10.1016/S1470-2045(16)30167-X ID - Younes2016 ER - TY - JOUR AU - Goodman, A. M. AU - Kato, S. AU - Bazhenova, L. AU - Patel, S. P. AU - Frampton, G. M. AU - Miller, V. PY - 2017 DA - 2017// TI - Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-17-0386 DO - 10.1158/1535-7163.MCT-17-0386 ID - Goodman2017 ER - TY - JOUR AU - Keenan, T. E. AU - Burke, K. P. AU - Allen, E. M. PY - 2019 DA - 2019// TI - Genomic correlates of response to immune checkpoint blockade JO - Nat Med VL - 25 UR - https://doi.org/10.1038/s41591-019-0382-x DO - 10.1038/s41591-019-0382-x ID - Keenan2019 ER - TY - JOUR AU - Liang, W. S. AU - Vergilio, J. A. AU - Salhia, B. AU - Huang, H. J. AU - Oki, Y. AU - Garrido-Laguna, I. PY - 2019 DA - 2019// TI - Comprehensive genomic profiling of Hodgkin lymphoma reveals recurrently mutated genes and increased mutation burden JO - Oncologist. VL - 24 UR - https://doi.org/10.1634/theoncologist.2018-0058 DO - 10.1634/theoncologist.2018-0058 ID - Liang2019 ER - TY - JOUR AU - Xu-Monette, Z. Y. AU - Zhou, J. AU - Young, K. H. PY - 2018 DA - 2018// TI - PD-1 expression and clinical PD-1 blockade in B-cell lymphomas JO - Blood. VL - 131 UR - https://doi.org/10.1182/blood-2017-07-740993 DO - 10.1182/blood-2017-07-740993 ID - Xu-Monette2018 ER - TY - JOUR AU - Green, M. R. AU - Rodig, S. AU - Juszczynski, P. AU - Ouyang, J. AU - Sinha, P. AU - O'Donnell, E. PY - 2012 DA - 2012// TI - Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-1942 DO - 10.1158/1078-0432.CCR-11-1942 ID - Green2012 ER - TY - JOUR AU - Roemer, M. G. AU - Advani, R. H. AU - Ligon, A. H. AU - Natkunam, Y. AU - Redd, R. A. AU - Homer, H. PY - 2016 DA - 2016// TI - PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.66.4482 DO - 10.1200/JCO.2016.66.4482 ID - Roemer2016 ER - TY - JOUR AU - Carbone, A. AU - Gloghini, A. AU - Carlo-Stella, C. PY - 2018 DA - 2018// TI - Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade? JO - Blood. VL - 132 UR - https://doi.org/10.1182/blood-2018-02-833806 DO - 10.1182/blood-2018-02-833806 ID - Carbone2018 ER - TY - JOUR AU - Scott, D. W. AU - Gascoyne, R. D. PY - 2014 DA - 2014// TI - The tumour microenvironment in B cell lymphomas JO - Nat Rev Cancer VL - 14 UR - https://doi.org/10.1038/nrc3774 DO - 10.1038/nrc3774 ID - Scott2014 ER - TY - JOUR AU - Kline, J. AU - Godfrey, J. AU - Ansell, S. M. PY - 2020 DA - 2020// TI - The immune landscape and response to immune checkpoint blockade therapy in lymphoma JO - Blood. VL - 135 UR - https://doi.org/10.1182/blood.2019000847 DO - 10.1182/blood.2019000847 ID - Kline2020 ER - TY - JOUR AU - Cader, F. Z. AU - Schackmann, R. C. J. AU - Hu, X. AU - Wienand, K. AU - Redd, R. AU - Chapuy, B. PY - 2018 DA - 2018// TI - Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted T-effector microenvironment JO - Blood. VL - 132 UR - https://doi.org/10.1182/blood-2018-04-843714 DO - 10.1182/blood-2018-04-843714 ID - Cader2018 ER - TY - JOUR AU - Roemer, M. G. M. AU - Redd, R. A. AU - Cader, F. Z. AU - Pak, C. J. AU - Abdelrahman, S. AU - Ouyang, J. PY - 2018 DA - 2018// TI - Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.77.3994 DO - 10.1200/JCO.2017.77.3994 ID - Roemer2018 ER - TY - JOUR AU - Patel, S. S. AU - Weirather, J. L. AU - Lipschitz, M. AU - Lako, A. AU - Chen, P. H. AU - Griffin, G. K. PY - 2019 DA - 2019// TI - The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative JO - Blood. VL - 134 ID - Patel2019 ER - TY - JOUR AU - Aoki, T. AU - Chong, L. C. AU - Takata, K. AU - Milne, K. AU - Hav, M. AU - Colombo, A. PY - 2020 DA - 2020// TI - Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma JO - Cancer Discov. VL - 10 UR - https://doi.org/10.1158/2159-8290.CD-19-0680 DO - 10.1158/2159-8290.CD-19-0680 ID - Aoki2020 ER - TY - JOUR AU - Vari, F. AU - Arpon, D. AU - Keane, C. AU - Hertzberg, M. S. AU - Talaulikar, D. AU - Jain, S. PY - 2018 DA - 2018// TI - Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL JO - Blood. VL - 131 UR - https://doi.org/10.1182/blood-2017-07-796342 DO - 10.1182/blood-2017-07-796342 ID - Vari2018 ER - TY - JOUR AU - Younes, A. AU - Brody, J. AU - Carpio, C. AU - Lopez-Guillermo, A. AU - Ben-Yehuda, D. AU - Ferhanoglu, B. PY - 2019 DA - 2019// TI - Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study JO - Lancet Haematol VL - 6 UR - https://doi.org/10.1016/S2352-3026(18)30217-5 DO - 10.1016/S2352-3026(18)30217-5 ID - Younes2019 ER - TY - JOUR AU - Pericart, S. AU - Tosolini, M. AU - Gravelle, P. AU - Rossi, C. AU - Traverse-Glehen, A. AU - Amara, N. PY - 2018 DA - 2018// TI - Profiling immune escape in Hodgkin’s and diffuse large B-cell lymphomas using the transcriptome and immunostaining JO - Cancers (Basel) VL - 10 UR - https://doi.org/10.3390/cancers10110415 DO - 10.3390/cancers10110415 ID - Pericart2018 ER - TY - JOUR AU - Keane, C. AU - Vari, F. AU - Hertzberg, M. AU - Cao, K. A. AU - Green, M. R. AU - Han, E. PY - 2015 DA - 2015// TI - Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study JO - Lancet Haematol. VL - 2 UR - https://doi.org/10.1016/S2352-3026(15)00150-7 DO - 10.1016/S2352-3026(15)00150-7 ID - Keane2015 ER - TY - JOUR AU - Xu-Monette, Z. Y. AU - Xiao, M. AU - Au, Q. AU - Padmanabhan, R. AU - Xu, B. AU - Hoe, N. PY - 2019 DA - 2019// TI - Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL JO - Cancer Immunol Res. VL - 7 UR - https://doi.org/10.1158/2326-6066.CIR-18-0439 DO - 10.1158/2326-6066.CIR-18-0439 ID - Xu-Monette2019 ER - TY - JOUR AU - Ennishi, D. AU - Jiang, A. AU - Boyle, M. AU - Collinge, B. AU - Grande, B. M. AU - Ben-Neriah, S. PY - 2019 DA - 2019// TI - Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.18.01583 DO - 10.1200/JCO.18.01583 ID - Ennishi2019 ER - TY - JOUR AU - Wang, X. AU - Cao, X. AU - Sun, R. AU - Tang, C. AU - Tzankov, A. AU - Zhang, J. PY - 2018 DA - 2018// TI - Clinical significance of PTEN deletion, mutation, and loss of PTEN expression in de novo diffuse large B-cell lymphoma JO - Neoplasia. VL - 20 UR - https://doi.org/10.1016/j.neo.2018.03.002 DO - 10.1016/j.neo.2018.03.002 ID - Wang2018 ER - TY - JOUR AU - Jiang, X. N. AU - Yu, B. H. AU - Yan, W. H. AU - Lee, J. AU - Zhou, X. Y. AU - Li, X. Q. PY - 2020 DA - 2020// TI - Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression JO - Oncoimmunology. VL - 9 UR - https://doi.org/10.1080/2162402X.2019.1683346 DO - 10.1080/2162402X.2019.1683346 ID - Jiang2020 ER - TY - JOUR AU - Ennishi, D. AU - Takata, K. AU - Beguelin, W. AU - Duns, G. AU - Mottok, A. AU - Farinha, P. PY - 2019 DA - 2019// TI - Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition JO - Cancer Discov VL - 9 UR - https://doi.org/10.1158/2159-8290.CD-18-1090 DO - 10.1158/2159-8290.CD-18-1090 ID - Ennishi2019 ER - TY - STD TI - Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, Lam EYN, et al. An evolutionarily conserved function of polycomb silences the MHC Class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell. 2019;36(4):385–401.e8. ID - ref84 ER - TY - JOUR AU - Grywalska, E. AU - Rolinski, J. PY - 2015 DA - 2015// TI - Epstein-Barr virus-associated lymphomas JO - Semin Oncol VL - 42 UR - https://doi.org/10.1053/j.seminoncol.2014.12.030 DO - 10.1053/j.seminoncol.2014.12.030 ID - Grywalska2015 ER - TY - JOUR AU - Kim, S. J. AU - Hyeon, J. AU - Cho, I. AU - Ko, Y. H. AU - Kim, W. S. PY - 2019 DA - 2019// TI - Comparison of efficacy of pembrolizumab between Epstein-Barr virus–positive and –negative relapsed or refractory non-Hodgkin lymphomas JO - Cancer Res Treat VL - 51 UR - https://doi.org/10.4143/crt.2018.191 DO - 10.4143/crt.2018.191 ID - Kim2019 ER - TY - JOUR AU - Kataoka, K. AU - Miyoshi, H. AU - Sakata, S. AU - Dobashi, A. AU - Couronné, L. AU - Kogure, Y. PY - 2019 DA - 2019// TI - Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas JO - Leukemia. VL - 33 UR - https://doi.org/10.1038/s41375-019-0380-5 DO - 10.1038/s41375-019-0380-5 ID - Kataoka2019 ER - TY - JOUR AU - Godfrey, J. AU - Tumuluru, S. AU - Bao, R. AU - Leukam, M. AU - Venkataraman, G. AU - Phillip, J. PY - 2019 DA - 2019// TI - PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype JO - Blood. VL - 133 UR - https://doi.org/10.1182/blood-2018-10-879015 DO - 10.1182/blood-2018-10-879015 ID - Godfrey2019 ER - TY - JOUR AU - Kwong, Y. L. AU - Chan, T. S. Y. AU - Tan, D. AU - Kim, S. J. AU - Poon, L. M. AU - Mow, B. PY - 2017 DA - 2017// TI - PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase JO - Blood. VL - 129 UR - https://doi.org/10.1182/blood-2016-12-756841 DO - 10.1182/blood-2016-12-756841 ID - Kwong2017 ER - TY - JOUR AU - Li, X. AU - Cheng, Y. AU - Zhang, M. AU - Yan, J. AU - Li, L. AU - Fu, X. PY - 2018 DA - 2018// TI - Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0559-7 DO - 10.1186/s13045-018-0559-7 ID - Li2018 ER - TY - JOUR AU - Barta, S. K. AU - Zain, J. AU - MacFarlane, A. W. AU - Smith, S. M. AU - Ruan, J. AU - Fung, H. C. PY - 2019 DA - 2019// TI - Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma JO - Clin Lymphoma Myeloma Leuk VL - 19 UR - https://doi.org/10.1016/j.clml.2019.03.022 DO - 10.1016/j.clml.2019.03.022 ID - Barta2019 ER - TY - JOUR AU - Ratner, L. AU - Waldmann, T. A. AU - Janakiram, M. AU - Brammer, J. E. PY - 2018 DA - 2018// TI - Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMc1803181 DO - 10.1056/NEJMc1803181 ID - Ratner2018 ER - TY - JOUR AU - Rauch, D. A. AU - Conlon, K. C. AU - Janakiram, M. AU - Brammer, J. E. AU - Harding, J. C. AU - Ye, B. H. PY - 2019 DA - 2019// TI - Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade JO - Blood. VL - 134 UR - https://doi.org/10.1182/blood.2019002038 DO - 10.1182/blood.2019002038 ID - Rauch2019 ER - TY - JOUR AU - Wartewig, T. AU - Kurgyis, Z. AU - Keppler, S. AU - Pechloff, K. AU - Hameister, E. AU - Öllinger, R. PY - 2017 DA - 2017// TI - PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis JO - Nature. VL - 552 UR - https://doi.org/10.1038/nature24649 DO - 10.1038/nature24649 ID - Wartewig2017 ER - TY - STD TI - Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood. 2020. Jul 9;blood.2020006540. ID - ref95 ER - TY - JOUR AU - Zhao, Y. AU - Shao, Q. AU - Peng, G. PY - 2020 DA - 2020// TI - Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment JO - Cell Mol Immunol. VL - 17 UR - https://doi.org/10.1038/s41423-019-0344-8 DO - 10.1038/s41423-019-0344-8 ID - Zhao2020 ER - TY - STD TI - Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, et al. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight. 2019;5. ID - ref97 ER - TY - JOUR AU - Chung, D. J. AU - Pronschinske, K. B. AU - Shyer, J. A. AU - Sharma, S. AU - Leung, S. AU - Curran, S. A. PY - 2016 DA - 2016// TI - T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy JO - Cancer Immunol Res VL - 4 UR - https://doi.org/10.1158/2326-6066.CIR-15-0055 DO - 10.1158/2326-6066.CIR-15-0055 ID - Chung2016 ER - TY - STD TI - Nakamura K, Kassem S, Cleynen A, Chretien ML, Guillerey C, Putz EM, et al. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell. 2018;33(4):634–48.e5. ID - ref99 ER - TY - JOUR AU - Krejcik, J. AU - Casneuf, T. AU - Nijhof, I. S. AU - Verbist, B. AU - Bald, J. AU - Plesner, T. PY - 2016 DA - 2016// TI - Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma JO - Blood. VL - 128 UR - https://doi.org/10.1182/blood-2015-12-687749 DO - 10.1182/blood-2015-12-687749 ID - Krejcik2016 ER - TY - JOUR AU - Badros, A. Z. AU - Ma, N. AU - Rapoport, A. P. AU - Lederer, E. AU - Lesokhin, A. M. PY - 2019 DA - 2019// TI - Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma JO - Blood Adv. VL - 3 UR - https://doi.org/10.1182/bloodadvances.2019000191 DO - 10.1182/bloodadvances.2019000191 ID - Badros2019 ER - TY - JOUR AU - Guillerey, C. AU - Harjunpää, H. AU - Carrié, N. AU - Kassem, S. AU - Teo, T. AU - Miles, K. PY - 2018 DA - 2018// TI - TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-01-825265 DO - 10.1182/blood-2018-01-825265 ID - Guillerey2018 ER - TY - JOUR AU - Berger, R. AU - Rotem-Yehudar, R. AU - Slama, G. AU - Landes, S. AU - Kneller, A. AU - Leiba, M. PY - 2008 DA - 2008// TI - Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-4079 DO - 10.1158/1078-0432.CCR-07-4079 ID - Berger2008 ER - TY - JOUR AU - Garcia-Manero, G. AU - Tallman, M. S. AU - Martinelli, G. AU - Ribrag, V. AU - Yang, H. AU - Balakumaran, A. PY - 2016 DA - 2016// TI - Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment JO - Blood VL - 128 UR - https://doi.org/10.1182/blood.V128.22.345.345 DO - 10.1182/blood.V128.22.345.345 ID - Garcia-Manero2016 ER - TY - JOUR AU - Zeidan, A. M. AU - Knaus, H. A. AU - Robinson, T. M. AU - Towlerton, A. M. H. AU - Warren, E. H. AU - Zeidner, J. F. PY - 2018 DA - 2018// TI - A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-3763 DO - 10.1158/1078-0432.CCR-17-3763 ID - Zeidan2018 ER - TY - JOUR AU - Liao, D. AU - Wang, M. AU - Liao, Y. AU - Li, J. AU - Niu, T. PY - 2019 DA - 2019// TI - A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia JO - Front Pharmacol VL - 10 UR - https://doi.org/10.3389/fphar.2019.00609 DO - 10.3389/fphar.2019.00609 ID - Liao2019 ER - TY - JOUR AU - Kong, Y. AU - Zhu, L. AU - Schell, T. D. AU - Zhang, J. AU - Claxton, D. F. AU - Ehmann, W. C. PY - 2016 DA - 2016// TI - T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2626 DO - 10.1158/1078-0432.CCR-15-2626 ID - Kong2016 ER - TY - JOUR AU - Wang, M. AU - Bu, J. AU - Zhou, M. AU - Sido, J. AU - Lin, Y. AU - Liu, G. PY - 2018 DA - 2018// TI - CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients JO - Clin Immunol VL - 190 UR - https://doi.org/10.1016/j.clim.2017.08.021 DO - 10.1016/j.clim.2017.08.021 ID - Wang2018 ER - TY - JOUR AU - Christopher, M. J. AU - Petti, A. A. AU - Rettig, M. P. AU - Miller, C. A. AU - Chendamarai, E. AU - Duncavage, E. J. PY - 2018 DA - 2018// TI - Immune escape of relapsed AML cells after allogeneic transplantation JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1808777 DO - 10.1056/NEJMoa1808777 ID - Christopher2018 ER - TY - JOUR AU - Kong, Y. AU - Zhang, J. AU - Claxton, D. F. AU - Ehmann, W. C. AU - Rybka, W. B. AU - Zhu, L. PY - 2015 DA - 2015// TI - PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation JO - Blood Cancer J VL - 5 UR - https://doi.org/10.1038/bcj.2015.58 DO - 10.1038/bcj.2015.58 ID - Kong2015 ER - TY - JOUR AU - Vannucchi, A. M. AU - Harrison, C. N. PY - 2017 DA - 2017// TI - Emerging treatments for classical myeloproliferative neoplasms JO - Blood. VL - 129 UR - https://doi.org/10.1182/blood-2016-10-695965 DO - 10.1182/blood-2016-10-695965 ID - Vannucchi2017 ER - TY - JOUR AU - Prestipino, A. AU - Emhardt, A. J. AU - Aumann, K. AU - O'Sullivan, D. AU - Gorantla, S. P. AU - Duquesne, S. PY - 2018 DA - 2018// JO - Sci Transl Med VL - 10 UR - https://doi.org/10.1126/scitranslmed.aam7729 DO - 10.1126/scitranslmed.aam7729 ID - Prestipino2018 ER - TY - JOUR AU - Holmström, M. O. AU - Hjortsø, M. D. AU - Ahmad, S. M. AU - Met, Ö. AU - Martinenaite, E. AU - Riley, C. PY - 2017 DA - 2017// TI - The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms JO - Leukemia. VL - 31 UR - https://doi.org/10.1038/leu.2016.290 DO - 10.1038/leu.2016.290 ID - Holmström2017 ER - TY - JOUR AU - Klampfl, T. AU - Gisslinger, H. AU - Harutyunyan, A. S. AU - Nivarthi, H. AU - Rumi, E. AU - Milosevic, J. D. PY - 2013 DA - 2013// TI - Somatic mutations of calreticulin in myeloproliferative neoplasms JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1311347 DO - 10.1056/NEJMoa1311347 ID - Klampfl2013 ER - TY - JOUR AU - Cimen Bozkus, C. AU - Roudko, V. AU - Finnigan, J. P. AU - Mascarenhas, J. AU - Hoffman, R. AU - Iancu-Rubin, C. PY - 2019 DA - 2019// TI - Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms JO - Cancer Discov. VL - 9 UR - https://doi.org/10.1158/2159-8290.CD-18-1356 DO - 10.1158/2159-8290.CD-18-1356 ID - Cimen Bozkus2019 ER - TY - JOUR AU - Holmström, M. O. AU - Martinenaite, E. AU - Ahmad, S. M. AU - Met, Ö. AU - Friese, C. AU - Kjær, L. PY - 2018 DA - 2018// TI - The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy JO - Leukemia. VL - 32 UR - https://doi.org/10.1038/leu.2017.214 DO - 10.1038/leu.2017.214 ID - Holmström2018 ER - TY - JOUR AU - Andrews, L. P. AU - Marciscano, A. E. AU - Drake, C. G. AU - Vignali, D. A. PY - 2017 DA - 2017// TI - LAG3 (CD223) as a cancer immunotherapy target JO - Immunol Rev VL - 276 UR - https://doi.org/10.1111/imr.12519 DO - 10.1111/imr.12519 ID - Andrews2017 ER - TY - JOUR AU - Maruhashi, T. AU - Okazaki, I. M. AU - Sugiura, D. AU - Takahashi, S. AU - Maeda, T. K. AU - Shimizu, K. PY - 2018 DA - 2018// TI - LAG-3 inhibits the activation of CD4(+) T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII JO - Nat Immunol VL - 19 UR - https://doi.org/10.1038/s41590-018-0217-9 DO - 10.1038/s41590-018-0217-9 ID - Maruhashi2018 ER - TY - JOUR AU - Grosso, J. F. AU - Kelleher, C. C. AU - Harris, T. J. AU - Maris, C. H. AU - Hipkiss, E. L. AU - Marzo, A. PY - 2007 DA - 2007// TI - LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems JO - J Clin Invest VL - 117 UR - https://doi.org/10.1172/JCI31184 DO - 10.1172/JCI31184 ID - Grosso2007 ER - TY - JOUR AU - Woo, S. R. AU - Turnis, M. E. AU - Goldberg, M. V. AU - Bankoti, J. AU - Selby, M. AU - Nirschl, C. J. PY - 2012 DA - 2012// TI - Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-1620 DO - 10.1158/0008-5472.CAN-11-1620 ID - Woo2012 ER - TY - JOUR AU - Wang, J. AU - Sanmamed, M. F. AU - Datar, I. AU - Su, T. T. AU - Ji, L. AU - Sun, J. PY - 2019 DA - 2019// TI - Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3 JO - Cell VL - 176 UR - https://doi.org/10.1016/j.cell.2018.11.010 DO - 10.1016/j.cell.2018.11.010 ID - Wang2019 ER - TY - JOUR AU - Keane, C. AU - Law, S. C. AU - Gould, C. AU - Birch, S. AU - Sabdia, M. B. PY - 2020 DA - 2020// TI - Merida de Long L, et al. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma JO - Blood Adv VL - 4 UR - https://doi.org/10.1182/bloodadvances.2019001390 DO - 10.1182/bloodadvances.2019001390 ID - Keane2020 ER - TY - JOUR AU - Koyama, S. AU - Akbay, E. A. AU - Li, Y. Y. AU - Herter-Sprie, G. S. AU - Buczkowski, K. A. AU - Richards, W. G. PY - 2016 DA - 2016// TI - Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms10501 DO - 10.1038/ncomms10501 ID - Koyama2016 ER - TY - JOUR AU - Ngiow, S. F. AU - Scheidt, B. AU - Akiba, H. AU - Yagita, H. AU - Teng, M. W. AU - Smyth, M. J. PY - 2011 DA - 2011// TI - Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-11-0096 DO - 10.1158/0008-5472.CAN-11-0096 ID - Ngiow2011 ER - TY - JOUR AU - Sakuishi, K. AU - Apetoh, L. AU - Sullivan, J. M. AU - Blazar, B. R. AU - Kuchroo, V. K. AU - Anderson, A. C. PY - 2010 DA - 2010// TI - Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity JO - J Exp Med VL - 207 UR - https://doi.org/10.1084/jem.20100643 DO - 10.1084/jem.20100643 ID - Sakuishi2010 ER - TY - JOUR AU - Anderson, A. C. PY - 2014 DA - 2014// TI - Tim-3: an emerging target in the cancer immunotherapy landscape JO - Cancer Immunol Res. VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-14-0039 DO - 10.1158/2326-6066.CIR-14-0039 ID - Anderson2014 ER - TY - JOUR AU - Mingo, P. Á. AU - Gardner, A. AU - Hiebler, S. AU - Soliman, H. AU - Rugo, H. S. AU - Krummel, M. F. PY - 2018 DA - 2018// TI - TIM-3 regulates CD103(+) dendritic cell function and response to chemotherapy in breast cancer JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2017.11.019 DO - 10.1016/j.ccell.2017.11.019 ID - Mingo2018 ER - TY - JOUR AU - Huang, X. AU - Bai, X. AU - Cao, Y. AU - Wu, J. AU - Huang, M. AU - Tang, D. PY - 2010 DA - 2010// TI - Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion JO - J Exp Med VL - 207 UR - https://doi.org/10.1084/jem.20090397 DO - 10.1084/jem.20090397 ID - Huang2010 ER - TY - JOUR AU - Kikushige, Y. AU - Shima, T. AU - Takayanagi, S. AU - Urata, S. AU - Miyamoto, T. AU - Iwasaki, H. PY - 2010 DA - 2010// TI - TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells JO - Cell Stem Cell VL - 7 UR - https://doi.org/10.1016/j.stem.2010.11.014 DO - 10.1016/j.stem.2010.11.014 ID - Kikushige2010 ER - TY - JOUR AU - Kikushige, Y. AU - Miyamoto, T. AU - Yuda, J. AU - Jabbarzadeh-Tabrizi, S. AU - Shima, T. AU - Takayanagi, S. PY - 2015 DA - 2015// TI - A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression JO - Cell Stem Cell VL - 17 UR - https://doi.org/10.1016/j.stem.2015.07.011 DO - 10.1016/j.stem.2015.07.011 ID - Kikushige2015 ER - TY - JOUR AU - Li, C. AU - Chen, X. AU - Yu, X. AU - Zhu, Y. AU - Ma, C. AU - Xia, R. PY - 2014 DA - 2014// TI - Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification JO - Int J Clin Exp Pathol VL - 7 ID - Li2014 ER - TY - STD TI - Harding JJ, Patnaik A, Moreno V, Stein M, Jankowska AM, Mendizabal NVd, et al. A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): interim safety, efficacy, and pharmacokinetic findings in advanced cancers. J Clin Oncol. 2019;37(8_suppl):12. ID - ref132 ER - TY - JOUR AU - Blake, S. J. AU - Dougall, W. C. AU - Miles, J. J. AU - Teng, M. W. AU - Smyth, M. J. PY - 2016 DA - 2016// TI - Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-16-0933 DO - 10.1158/1078-0432.CCR-16-0933 ID - Blake2016 ER - TY - JOUR AU - Zhu, Y. AU - Paniccia, A. AU - Schulick, A. C. AU - Chen, W. AU - Koenig, M. R. AU - Byers, J. T. PY - 2016 DA - 2016// TI - Identification of CD112R as a novel checkpoint for human T cells JO - J Exp Med VL - 213 UR - https://doi.org/10.1084/jem.20150785 DO - 10.1084/jem.20150785 ID - Zhu2016 ER - TY - JOUR AU - Manieri, N. A. AU - Chiang, E. Y. AU - Grogan, J. L. PY - 2017 DA - 2017// TI - TIGIT: a key inhibitor of the cancer immunity cycle JO - Trends Immunol VL - 38 UR - https://doi.org/10.1016/j.it.2016.10.002 DO - 10.1016/j.it.2016.10.002 ID - Manieri2017 ER - TY - JOUR AU - Kurtulus, S. AU - Sakuishi, K. AU - Ngiow, S. F. AU - Joller, N. AU - Tan, D. J. AU - Teng, M. W. PY - 2015 DA - 2015// TI - TIGIT predominantly regulates the immune response via regulatory T cells JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI81187 DO - 10.1172/JCI81187 ID - Kurtulus2015 ER - TY - JOUR AU - Minnie, S. A. AU - Kuns, R. D. AU - Gartlan, K. H. AU - Zhang, P. AU - Wilkinson, A. N. AU - Samson, L. PY - 2018 DA - 2018// TI - Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade JO - Blood. VL - 132 UR - https://doi.org/10.1182/blood-2018-01-825240 DO - 10.1182/blood-2018-01-825240 ID - Minnie2018 ER - TY - JOUR AU - Zhang, Q. AU - Bi, J. AU - Zheng, X. AU - Chen, Y. AU - Wang, H. AU - Wu, W. PY - 2018 DA - 2018// TI - Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity JO - Nat Immunol VL - 19 UR - https://doi.org/10.1038/s41590-018-0132-0 DO - 10.1038/s41590-018-0132-0 ID - Zhang2018 ER - TY - JOUR AU - Guillerey, C. AU - Huntington, N. D. AU - Smyth, M. J. PY - 2016 DA - 2016// TI - Targeting natural killer cells in cancer immunotherapy JO - Nat Immunol VL - 17 UR - https://doi.org/10.1038/ni.3518 DO - 10.1038/ni.3518 ID - Guillerey2016 ER - TY - JOUR AU - Nakamura, K. AU - Smyth, M. J. PY - 2020 DA - 2020// TI - Myeloid immunosuppression and immune checkpoints in the tumor microenvironment JO - Cell Mol Immunol VL - 17 UR - https://doi.org/10.1038/s41423-019-0306-1 DO - 10.1038/s41423-019-0306-1 ID - Nakamura2020 ER - TY - JOUR AU - Raulet, D. H. AU - Vance, R. E. PY - 2006 DA - 2006// TI - Self-tolerance of natural killer cells JO - Nat Rev Immunol VL - 6 UR - https://doi.org/10.1038/nri1863 DO - 10.1038/nri1863 ID - Raulet2006 ER - TY - JOUR AU - Kamiya, T. AU - Seow, S. V. AU - Wong, D. AU - Robinson, M. AU - Campana, D. PY - 2019 DA - 2019// TI - Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells JO - J Clin Invest VL - 129 UR - https://doi.org/10.1172/JCI123955 DO - 10.1172/JCI123955 ID - Kamiya2019 ER - TY - JOUR AU - Mahaweni, N. M. AU - Ehlers, F. A. I. AU - Bos, G. M. J. AU - Wieten, L. PY - 2018 DA - 2018// TI - Tuning natural killer cell anti-multiple myeloma reactivity by targeting inhibitory signaling via KIR and NKG2A JO - Front Immunol VL - 9 UR - https://doi.org/10.3389/fimmu.2018.02848 DO - 10.3389/fimmu.2018.02848 ID - Mahaweni2018 ER - TY - JOUR AU - André, P. AU - Denis, C. AU - Soulas, C. AU - Bourbon-Caillet, C. AU - Lopez, J. AU - Arnoux, T. PY - 2018 DA - 2018// TI - Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells JO - Cell VL - 175 UR - https://doi.org/10.1016/j.cell.2018.10.014 DO - 10.1016/j.cell.2018.10.014 ID - André2018 ER - TY - JOUR AU - Benson, D. M. AU - Hofmeister, C. C. AU - Padmanabhan, S. AU - Suvannasankha, A. AU - Jagannath, S. AU - Abonour, R. PY - 2012 DA - 2012// TI - A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma JO - Blood. VL - 120 UR - https://doi.org/10.1182/blood-2012-06-438028 DO - 10.1182/blood-2012-06-438028 ID - Benson2012 ER - TY - JOUR AU - Vey, N. AU - Bourhis, J. H. AU - Boissel, N. AU - Bordessoule, D. AU - Prebet, T. AU - Charbonnier, A. PY - 2012 DA - 2012// TI - A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission JO - Blood. VL - 120 UR - https://doi.org/10.1182/blood-2012-06-437558 DO - 10.1182/blood-2012-06-437558 ID - Vey2012 ER - TY - JOUR AU - Korde, N. AU - Carlsten, M. AU - Lee, M. J. AU - Minter, A. AU - Tan, E. AU - Kwok, M. PY - 2014 DA - 2014// TI - A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma JO - Haematologica. VL - 99 UR - https://doi.org/10.3324/haematol.2013.103085 DO - 10.3324/haematol.2013.103085 ID - Korde2014 ER - TY - JOUR AU - Benson, D. M. AU - Cohen, A. D. AU - Jagannath, S. AU - Munshi, N. C. AU - Spitzer, G. AU - Hofmeister, C. C. PY - 2015 DA - 2015// TI - A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0304 DO - 10.1158/1078-0432.CCR-15-0304 ID - Benson2015 ER - TY - STD TI - Armand P, Lesokhin A, Borrello I, Timmerman J, Gutierrez M, Zhu L, et al. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia. 2020. ID - ref149 ER - TY - JOUR AU - Feng, M. AU - Jiang, W. AU - Kim, B. Y. S. AU - Zhang, C. C. AU - Fu, Y. X. AU - Weissman, I. L. PY - 2019 DA - 2019// TI - Phagocytosis checkpoints as new targets for cancer immunotherapy JO - Nat Rev Cancer VL - 19 UR - https://doi.org/10.1038/s41568-019-0183-z DO - 10.1038/s41568-019-0183-z ID - Feng2019 ER - TY - JOUR AU - Barclay, A. N. AU - Brown, M. H. PY - 2006 DA - 2006// TI - The SIRP family of receptors and immune regulation JO - Nat Rev Immunol. VL - 6 UR - https://doi.org/10.1038/nri1859 DO - 10.1038/nri1859 ID - Barclay2006 ER - TY - JOUR AU - Liu, X. AU - Pu, Y. AU - Cron, K. AU - Deng, L. AU - Kline, J. AU - Frazier, W. A. PY - 2015 DA - 2015// TI - CD47 blockade triggers T cell-mediated destruction of immunogenic tumors JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3931 DO - 10.1038/nm.3931 ID - Liu2015 ER - TY - JOUR AU - Chao, M. P. AU - Alizadeh, A. A. AU - Tang, C. AU - Myklebust, J. H. AU - Varghese, B. AU - Gill, S. PY - 2010 DA - 2010// TI - Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma JO - Cell. VL - 142 UR - https://doi.org/10.1016/j.cell.2010.07.044 DO - 10.1016/j.cell.2010.07.044 ID - Chao2010 ER - TY - JOUR AU - Advani, R. AU - Flinn, I. AU - Popplewell, L. AU - Forero, A. AU - Bartlett, N. L. AU - Ghosh, N. PY - 2018 DA - 2018// TI - CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1807315 DO - 10.1056/NEJMoa1807315 ID - Advani2018 ER - TY - JOUR AU - Barkal, A. A. AU - Weiskopf, K. AU - Kao, K. S. AU - Gordon, S. R. AU - Rosental, B. AU - Yiu, Y. Y. PY - 2018 DA - 2018// TI - Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy JO - Nat Immunol VL - 19 UR - https://doi.org/10.1038/s41590-017-0004-z DO - 10.1038/s41590-017-0004-z ID - Barkal2018 ER - TY - JOUR AU - Barkal, A. A. AU - Brewer, R. E. AU - Markovic, M. AU - Kowarsky, M. AU - Barkal, S. A. AU - Zaro, B. W. PY - 2019 DA - 2019// TI - CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy JO - Nature. VL - 572 UR - https://doi.org/10.1038/s41586-019-1456-0 DO - 10.1038/s41586-019-1456-0 ID - Barkal2019 ER - TY - STD TI - Nakamura K, Casey M, Oey H, Vari F, Stagg J, Gandhi MK, et al. Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia. 2020. https://doi.org/10.1038/s41375-020-0811-3. ID - ref157 ER - TY - JOUR AU - Jackson, H. J. AU - Rafiq, S. AU - Brentjens, R. J. PY - 2016 DA - 2016// TI - Driving CAR T-cells forward JO - Nat Rev Clin Oncol VL - 13 UR - https://doi.org/10.1038/nrclinonc.2016.36 DO - 10.1038/nrclinonc.2016.36 ID - Jackson2016 ER - TY - JOUR AU - Schuster, S. J. AU - Bishop, M. R. AU - Tam, C. S. AU - Waller, E. K. AU - Borchmann, P. AU - McGuirk, J. P. PY - 2019 DA - 2019// TI - Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMoa1804980 DO - 10.1056/NEJMoa1804980 ID - Schuster2019 ER - TY - JOUR AU - Neelapu, S. S. AU - Locke, F. L. AU - Bartlett, N. L. AU - Lekakis, L. J. AU - Miklos, D. B. AU - Jacobson, C. A. PY - 2017 DA - 2017// TI - Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1707447 DO - 10.1056/NEJMoa1707447 ID - Neelapu2017 ER - TY - JOUR AU - Locke, F. L. AU - Ghobadi, A. AU - Jacobson, C. A. AU - Miklos, D. B. AU - Lekakis, L. J. AU - Oluwole, O. O. PY - 2019 DA - 2019// TI - Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial JO - Lancet Oncol. VL - 20 UR - https://doi.org/10.1016/S1470-2045(18)30864-7 DO - 10.1016/S1470-2045(18)30864-7 ID - Locke2019 ER - TY - JOUR AU - Kochenderfer, J. N. AU - Somerville, R. P. T. AU - Lu, T. AU - Yang, J. C. AU - Sherry, R. M. AU - Feldman, S. A. PY - 2017 DA - 2017// TI - Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy JO - Mol Ther VL - 25 UR - https://doi.org/10.1016/j.ymthe.2017.07.004 DO - 10.1016/j.ymthe.2017.07.004 ID - Kochenderfer2017 ER - TY - JOUR AU - Kochenderfer, J. N. AU - Dudley, M. E. AU - Kassim, S. H. AU - Somerville, R. P. AU - Carpenter, R. O. AU - Stetler-Stevenson, M. PY - 2015 DA - 2015// TI - Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.56.2025 DO - 10.1200/JCO.2014.56.2025 ID - Kochenderfer2015 ER - TY - JOUR AU - Kochenderfer, J. N. AU - Dudley, M. E. AU - Feldman, S. A. AU - Wilson, W. H. AU - Spaner, D. E. AU - Maric, I. PY - 2012 DA - 2012// TI - B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells JO - Blood. VL - 119 UR - https://doi.org/10.1182/blood-2011-10-384388 DO - 10.1182/blood-2011-10-384388 ID - Kochenderfer2012 ER - TY - JOUR AU - Wang, M. AU - Munoz, J. AU - Goy, A. AU - Locke, F. L. AU - Jacobson, C. A. AU - Hill, B. T. PY - 2020 DA - 2020// TI - KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma JO - N Engl J Med VL - 382 UR - https://doi.org/10.1056/NEJMoa1914347 DO - 10.1056/NEJMoa1914347 ID - Wang2020 ER - TY - JOUR AU - Porter, D. L. AU - Hwang, W. T. AU - Frey, N. V. AU - Lacey, S. F. AU - Shaw, P. A. AU - Loren, A. W. PY - 2015 DA - 2015// TI - Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia JO - Sci Transl Med VL - 7 UR - https://doi.org/10.1126/scitranslmed.aac5415 DO - 10.1126/scitranslmed.aac5415 ID - Porter2015 ER - TY - JOUR AU - Maude, S. L. AU - Frey, N. AU - Shaw, P. A. AU - Aplenc, R. AU - Barrett, D. M. AU - Bunin, N. J. PY - 2014 DA - 2014// TI - Chimeric antigen receptor T cells for sustained remissions in leukemia JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1407222 DO - 10.1056/NEJMoa1407222 ID - Maude2014 ER - TY - JOUR AU - Fraietta, J. A. AU - Lacey, S. F. AU - Orlando, E. J. AU - Pruteanu-Malinici, I. AU - Gohil, M. AU - Lundh, S. PY - 2018 DA - 2018// TI - Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0010-1 DO - 10.1038/s41591-018-0010-1 ID - Fraietta2018 ER - TY - JOUR AU - Locke, F. L. AU - Westin, J. R. AU - Miklos, D. B. AU - Herrara, A. F. AU - Jacobson, C. A. AU - Lee, J. PY - 2017 DA - 2017// TI - Phase 1 results from ZUMA-6: axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL) JO - Blood VL - 130 ID - Locke2017 ER - TY - JOUR AU - Siddiqi, T. AU - Abramson, J. S. AU - Lee, H. J. AU - Schuster, S. AU - Hasskarl, J. AU - Montheard, S. PY - 2019 DA - 2019// TI - Safety of lisocabtagene maraleucel given with durvalumab in patients with relapsed/refractory aggressive B-cell non Hodgkin lymphoma: first results from the platform study JO - Hematol Oncol VL - 37 UR - https://doi.org/10.1002/hon.128_2629 DO - 10.1002/hon.128_2629 ID - Siddiqi2019 ER - TY - JOUR AU - Li, A. M. AU - Hucks, G. E. AU - Dinofia, A. M. AU - Seif, A. E. AU - Teachey, D. T. AU - Baniewicz, D. PY - 2018 DA - 2018// TI - Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia JO - Blood VL - 132 UR - https://doi.org/10.1182/blood-2018-99-112572 DO - 10.1182/blood-2018-99-112572 ID - Li2018 ER - TY - JOUR AU - Curran, K. J. AU - Seinstra, B. A. AU - Nikhamin, Y. AU - Yeh, R. AU - Usachenko, Y. AU - Leeuwen, D. G. PY - 2015 DA - 2015// TI - Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression JO - Mol Ther VL - 23 UR - https://doi.org/10.1038/mt.2015.4 DO - 10.1038/mt.2015.4 ID - Curran2015 ER - TY - STD TI - Lai J, Mardiana S, House IG, Sek K, Henderson MA, Giuffrida L, et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat Immunol. 2020;21(8):914–26. ID - ref173 ER - TY - JOUR AU - Yeku, O. O. AU - Purdon, T. J. AU - Koneru, M. AU - Spriggs, D. AU - Brentjens, R. J. PY - 2017 DA - 2017// TI - Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-10940-8 DO - 10.1038/s41598-017-10940-8 ID - Yeku2017 ER - TY - JOUR AU - Pegram, H. J. AU - Purdon, T. J. AU - Leeuwen, D. G. AU - Curran, K. J. AU - Giralt, S. A. AU - Barker, J. N. PY - 2015 DA - 2015// TI - IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia JO - Leukemia. VL - 29 UR - https://doi.org/10.1038/leu.2014.215 DO - 10.1038/leu.2014.215 ID - Pegram2015 ER - TY - JOUR AU - Avanzi, M. P. AU - Yeku, O. AU - Li, X. AU - Wijewarnasuriya, D. P. AU - Leeuwen, D. G. AU - Cheung, K. PY - 2018 DA - 2018// TI - Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system JO - Cell Rep VL - 23 UR - https://doi.org/10.1016/j.celrep.2018.04.051 DO - 10.1016/j.celrep.2018.04.051 ID - Avanzi2018 ER - TY - JOUR AU - Cherkassky, L. AU - Morello, A. AU - Villena-Vargas, J. AU - Feng, Y. AU - Dimitrov, D. S. AU - Jones, D. R. PY - 2016 DA - 2016// TI - Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition JO - J Clin Invest VL - 126 UR - https://doi.org/10.1172/JCI83092 DO - 10.1172/JCI83092 ID - Cherkassky2016 ER - TY - JOUR AU - Rupp, L. J. AU - Schumann, K. AU - Roybal, K. T. AU - Gate, R. E. AU - Ye, C. J. AU - Lim, W. A. PY - 2017 DA - 2017// TI - CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-00462-8 DO - 10.1038/s41598-017-00462-8 ID - Rupp2017 ER - TY - JOUR AU - Gautron, A. S. AU - Juillerat, A. AU - Guyot, V. AU - Filhol, J. M. AU - Dessez, E. AU - Duclert, A. PY - 2017 DA - 2017// TI - Fine and predictable tuning of TALEN gene editing targeting for improved T cell adoptive immunotherapy JO - Mol Ther Nucleic Acids VL - 9 UR - https://doi.org/10.1016/j.omtn.2017.10.005 DO - 10.1016/j.omtn.2017.10.005 ID - Gautron2017 ER - TY - JOUR AU - Rafiq, S. AU - Yeku, O. O. AU - Jackson, H. J. AU - Purdon, T. J. AU - Leeuwen, D. G. AU - Drakes, D. J. PY - 2018 DA - 2018// TI - Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo JO - Nat Biotechnol VL - 36 UR - https://doi.org/10.1038/nbt.4195 DO - 10.1038/nbt.4195 ID - Rafiq2018 ER - TY - JOUR AU - Neelapu, S. S. AU - Tummala, S. AU - Kebriaei, P. AU - Wierda, W. AU - Gutierrez, C. AU - Locke, F. L. PY - 2018 DA - 2018// TI - Chimeric antigen receptor T-cell therapy - assessment and management of toxicities JO - Nat Rev Clin Oncol VL - 15 UR - https://doi.org/10.1038/nrclinonc.2017.148 DO - 10.1038/nrclinonc.2017.148 ID - Neelapu2018 ER - TY - JOUR AU - Stasi, A. AU - Tey, S. K. AU - Dotti, G. AU - Fujita, Y. AU - Kennedy-Nasser, A. AU - Martinez, C. PY - 2011 DA - 2011// TI - Inducible apoptosis as a safety switch for adoptive cell therapy JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1106152 DO - 10.1056/NEJMoa1106152 ID - Stasi2011 ER - TY - JOUR AU - Sabatino, M. AU - Choi, K. AU - Chiruvolu, V. AU - Better, M. PY - 2016 DA - 2016// TI - Production of anti-CD19 CAR T cells for ZUMA-3 and -4: phase 1/2 multicenter studies evaluating KTE-C19 in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL) JO - Blood VL - 128 UR - https://doi.org/10.1182/blood.V128.22.1227.1227 DO - 10.1182/blood.V128.22.1227.1227 ID - Sabatino2016 ER - TY - JOUR AU - Velasquez, M. P. AU - Bonifant, C. L. AU - Gottschalk, S. PY - 2018 DA - 2018// TI - Redirecting T cells to hematological malignancies with bispecific antibodies JO - Blood. VL - 131 UR - https://doi.org/10.1182/blood-2017-06-741058 DO - 10.1182/blood-2017-06-741058 ID - Velasquez2018 ER - TY - JOUR AU - Wang, H. AU - Kaur, G. AU - Sankin, A. I. AU - Chen, F. AU - Guan, F. AU - Zang, X. PY - 2019 DA - 2019// TI - Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0746-1 DO - 10.1186/s13045-019-0746-1 ID - Wang2019 ER - TY - JOUR AU - Manson, G. AU - Mear, J. B. AU - Herbaux, C. AU - Schiano, J. M. AU - Casasnovas, O. AU - Stamatoullas, A. PY - 2019 DA - 2019// TI - Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation JO - Eur J Cancer VL - 115 UR - https://doi.org/10.1016/j.ejca.2019.04.006 DO - 10.1016/j.ejca.2019.04.006 ID - Manson2019 ER -